Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers
NCT ID: NCT01580644
Last Updated: 2012-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
12 participants
INTERVENTIONAL
2012-01-31
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Two formulations of the GLPG0187 prodrug will be compared, as well as the effect of food and dose proportionality of the best formulation.
Furthermore, during the course of the study, safety and tolerability will be characterized.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet
NCT03143712
Oral Bioavailability of Two Solid Formulations of GLPG0634
NCT01915667
GLPG0259 Solid Formulation Bioavailability and Food Effect
NCT01024517
Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667
NCT05335447
Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral Solution
NCT03143725
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Period 1: formulation 1 oral solution
GLPG0187 prodrug
Period 2: formulation 2 capsule
GLPG0187 prodrug
Period 3: Selected formulation + food
GLPG0187 prodrug
Period 4: Selected formulation at higher dose
GLPG0187 prodrug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GLPG0187 prodrug
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 18-30 kg/m2
Exclusion Criteria
* Drug or alcohol abuse
* Smoking
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galapagos NV
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frédéric Vanhoutte, MD
Role: STUDY_DIRECTOR
Galapagos NV
Eva Vets, MD
Role: PRINCIPAL_INVESTIGATOR
SGS Stuivenberg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SGS Stuivenberg
Antwerp, Antwerp, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GLPG0187-CL-104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.